|
Research Summary
Our research is divided roughly equally
between two main projects: 1) methods development for high-throughput protein
expression and purification; and 2) X-ray crystallographic studies of virulence
factors from potential agents of bioterrorism, with particular emphasis on the
plague-causing bacterium Yersinia pestis.
We previously demonstrated that E.
coli maltose binding protein (MBP) has a remarkable ability to enhance the
solubility and promote the proper folding of its fusion partners. For this
reason, and because MBP fusion proteins routinely accumulate to very high
levels in E. coli, we have made MBP the cornerstone of our approach for
high-throughput protein expression and purification. However, MBP fusion
proteins do not always bind efficiently to amylose resin, and even when they do
the fusion proteins are rarely pure after amylose affinity chromatography.
Therefore, to compensate for the relatively poor performance of MBP as an
affinity tag, we attempted to incorporate supplementary tags within the general
framework of an MBP fusion protein. We identified several locations within the
framework of an MBP fusion protein where accessory tags could be added without
compromising the ability of MBP to promote the solubility of its fusion
partners. We then designed and successfully tested a generic protocol for
protein production in E. coli that utilizes a dual
His6-MBP affinity tag. The MBP moiety improves the
yield and enhances the solubility of the passenger protein while the His-tag
facilitates its purification. We are currently working on applying this method
in other hosts for heterologous protein expression.
Because most affinity tags have the
potential to interfere with structural studies, reliable ways to remove them
are absolutely necessary. Accordingly, we have invested a substantial effort in
trying to exploit the highly specific tobacco etch virus (TEV) protease for
this purpose. To improve the solubility of TEV protease in E. coli, we
designed an expression vector that produces the enzyme in the form of an MBP
fusion protein that cleaves itself in vivo to generate an N-terminally
His-tagged TEV protease catalytic domain that is free of MBP. A dramatic
increase in the yield of TEV protease was realized by using a tRNA accessory
plasmid to compensate for the presence of arginine codons that are rarely used
in E. coli. We also devised a simple method for intracellular processing
of fusion proteins by TEV protease, which is used to determine whether or not a
passenger protein is likely to be properly folded when it is fused to MBP. We
have shown that many different amino acid side chains can be accommodated in
the P1′ site of a TEV protease recognition site with little or no impact
on the efficiency of processing. Consequently, in many cases it is possible to
use TEV protease to produce recombinant proteins with no non-native residues
attached to their N-termini. Wild-type TEV protease cleaves itself at a
specific site to generate a truncated polypeptide with greatly reduced
enzymatic activity. We managed to overcome the autolysis problem by
constructing a mutant enzyme (S219V) that is nearly impervious to
autoinactivation and almost twice as catalytically active as the wild-type
enzyme. We have distributed S219V TEV protease expression vectors to hundreds
of research laboratories around the world. We have also determined crystal
structures of TEV protease complexed with a peptide substrate and an inhibitor,
which revealed the structural basis of its stringent sequence specificity. We
are currently focusing on the characterization of other highly specific
proteases, such as that encoded by the tobacco vein mottling virus (TVMV),
which may prove to be useful alternatives to TEV protease.
Our success in producing large quantities
of crystallization-grade proteins led to a small-scale structural genomics
project aiming to solve the three-dimensional structures of proteins involved
in Type III secretion in Yersinia pestis, the causative agent of plague.
Because the Type III secretion system (T3SS) is essential for virulence, the
resulting structural information could be used to develop effective
countermeasures for this potential agent of bioterrorism. We have already
solved 12 novel structures and are in the process of solving more of them,
including several protein-protein complexes. In one case, we have already begun
the process of structure-based drug development. One of the cytotoxic effector
proteins that Yersinia injects into mammalian cells via the T3SS, YopH,
is a potent eukaryotic-like protein tyrosine phosphatase (PTPase). YopH
dephosphorylates several proteins associated with the focal adhesion in
eukaryotic cells, thereby enabling the bacterium to avoid phagocytosis and
destruction by macrophages. In collaboration with Dr. Terrence Burke Jr.
(Laboratory of Medicinal Chemistry, CCR) and Dr. Robert Ulrich (USAMRIID), we
have identified several compounds that inhibit YopH with IC50 values in the low
micromolar range. Thus far we have managed to crystallize one of these with the
enzyme and solve the co-crystal structure at 2.2 Å resolution. The
resulting structural information suggested several ways in which the potency of
the inhibitor might be improved, and these possibilities are currently being
explored. In addition, we have determined a high-resolution structure (1.5
Å) of the YopH PTPase in complex with a nonhydrolyzable hexapeptide
substrate analog, providing us with yet another starting point for the
development of inhibitors.
We have recently expanded our range of
targets for structural studies to include virulence factors from other
potential agents of bioterrorism, including the variola major (smallpox) virus
and Francisella tularensis, the causative agent of tularemia. Crystal
structures of proteins from both of these sources have recently been
determined. One of them is currently the focus of another structure-based drug
development project.
Additional ongoing structure-based drug
development projects being carried out in collaboration with intramural
investigators at the NIH include structural studies of HIV entry inhibitors,
Chk2 kinase inhibitors, and inhibitors of the Grb2 SH2 domain.
Our principal extramural collaborators are
Dr. József Tözér (University of Debrecen, Hungary), Dr.
Gregory Plano (University of Miami School of Medicine), and Dr. Robert Ulrich
(USAMRIID). |